Venus Remedies Limited (NSE: VENUSREM | BSE: 526953)
Source: Venus Remedies Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)
📋 Quick Facts: Company Snapshot
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Venus Remedies Limited |
| Corporate Identity Number (CIN) | L24232CH1989PLC009705 |
| ISIN | INE411B01019 |
| Stock Exchange Listing | NSE: VENUSREM | BSE: 526953 |
| Date of Incorporation / Founding Year | 15th September, 1989 |
| Founders / Key Founding Figures | Pawan Chaudhary |
| Registered Office & Corporate Headquarters | Registered Office: SCO 857, Cabin no. 10, 2nd Floor, NAC Manimajra, Chandigarh – 160101; Corporate Office: 51-52, Industrial Area, Phase-1, Panchkula – 134113, Haryana |
| Telephone & Official Investor Relations Email | Phone: 0172-2933090, Fax: 0172-2565566 | Email: complianceofficer@venusremedies.com |
| Chairman / Managing Director & CEO | Pawan Chaudhary (Chairman & Managing Director), Saransh Chaudhary (CEO – VMRC) |
| Chief Financial Officer (CFO) & Company Secretary (CS) | Pawan Chaudhary (CFO), Neha Kodan (Company Secretary) |
| Promoter & Holding Group | Pawan Chaudhary, Manu Chaudhary, and Sunev Pharma Solutions Private Limited |
| Industry / Sector Classification | Pharmaceutical Industry (Specialized in Complex Injectables, Critical Care, and Anti-Infectives) |
| Total Employees / Workforce | 1,472 Permanent Employees across 5 locations (16% female workforce) |
| Manufacturing Plants / Branches / Offices Count | 3 Manufacturing Facilities (Panchkula, Baddi, and Werne/Hungary via subsidiaries) |
| Statutory, Secretarial & Cost Auditors | M/s J.K. Jain & Associates (Statutory Auditors), M/s P. Chadha & Associates (Secretarial Auditors), M/s C. L. Bansal & Associates (Cost Auditors) |
| Registrar and Share Transfer Agent (RTA) | MUFG Intime India Private Limited (formerly Link Intime India Private Limited), New Delhi |
🏢 The Corporate Identity: Venus Remedies Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Venus Remedies Limited is a research-driven global pharmaceutical company specializing in complex injectable formulations, anti-infectives, oncology, critical care, and specialty therapies. Operating across more than 100 countries, the company combines robust manufacturing infrastructure with dedicated research capabilities anchored by the Venus Medicine Research Centre (VMRC). Its business model focuses on high-barrier sterile injectable products, antimicrobial resistance (AMR) mitigation, and proprietary drug delivery platforms, serving institutional, government, and private healthcare markets globally.
The Founders, Promoters & Their Legacy
The company is led by Pawan Chaudhary, Chairman and Managing Director, alongside co-founders and executive leaders including Dr. (Mrs.) Manu Chaudhary (Joint Managing Director & Director – Technical), Mr. Peeyush Jain, Mr. Ashutosh Jain, Mr. Akshansh Chaudhary, and Mr. Saransh Chaudhary. Over three decades, the founding leadership has steered Venus Remedies from a regional formulation player into an internationally recognized, research-driven institution holding over 150 global patents and more than 1,100 marketing authorisations.
The Journey: Corporate History & Key Milestones
Originally incorporated on September 15, 1989, as Venus Glucose Private Limited, the company progressively transitioned into complex injectables and critical care. Over subsequent decades, it established world-class manufacturing plants in Panchkula (Haryana) and Baddi (Himachal Pradesh), set up VMRC, expanded operations into Europe via German and Hungarian subsidiaries, and achieved major regulatory milestones including USFDA Qualified Infectious Disease Product (QIDP) designations for proprietary molecules such as VRP-034.
The Corporate Umbrella & Group Structure
The consolidated corporate structure comprises the holding company Venus Remedies Limited, its wholly owned foreign subsidiary Venus Pharma GmbH located in Werne, Germany, and a step-down subsidiary Venus Pharma Kft located in Hungary. Together, these entities form an integrated network for manufacturing, regulatory compliance, logistics, and international commercial distribution.
⚙️ The Business Engine: Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Venus Remedies derives its revenues primarily from pharmaceutical formulations categorized by therapeutic segments and geographic regions. The company operates in a single primary business segment: Pharmaceutical Formulations, engaging in the manufacture and distribution of specialized medicines.
| Therapy / Segment | Revenue (₹ Crores) | % Share of Total Revenue |
|---|---|---|
| Antibiotics (Anti-Infectives) | 443.51 | 57.63% |
| Anticancer (Oncology) | 175.52 | 22.81% |
| Anticoagulant | 39.97 | 5.19% |
| Analgesic | 33.40 | 4.34% |
| Others / Specialty Therapies | 77.20 | 10.03% |
| Total Revenue from Operations | 769.60 | 100.00% |
The Product & Service Catalog (with Operational KPIs & Order Book)
The company’s product portfolio exceeds 195+ formulations, backed by 700+ dossiers filed and 1,100+ global marketing authorisations. Key operational capabilities include a manufacturing capacity of 100 million injectable units per annum, hospital reach exceeding 12,000 institutions, and institutional supply chains spanning major government and private networks.
The Names You Know: Key Brands & Flagship Portfolio
Venus Remedies markets several established institutional and consumer brands across critical care, wound care, and natural wellness.
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| SUPIME | Anti-Infective / Critical Care | Advanced cephalosporin antibiotic positioned as a primary defense in severe hospital infections. |
| TROIS | Analgesic / Pain Management | Nanotechnology-based pain relief emulsion for targeted musculoskeletal care. |
| SEPTILOC | Wound Care / Topical | Specialized formulation for advanced wound management and infection control. |
| VENTAFUL A | Respiratory / Specialty Care | Therapeutic solution addressing COPD and asthma in hospital and clinical practice. |
| RESET | Consumer Healthcare / Wellness | Plant-based natural wellness and pain relief brand spanning topical oils and wellness accessories. |
Mapping the Domestic & Global Reach (India vs. Exports)
International markets account for the majority of the company’s revenues, supported by a commercial presence across 100+ countries.
| Geography / Region | Revenue (₹ Crores) | % Share of Total Revenue |
|---|---|---|
| India (Domestic) | 178.45 | 23.19% |
| Latin America (LATAM) | 142.78 | 18.55% |
| Europe | 133.31 | 17.32% |
| Middle East | 110.61 | 14.37% |
| Africa | 99.30 | 12.90% |
| Asia (Ex-India) | 94.64 | 12.30% |
| Others | 10.51 | 1.37% |
| Total Consolidated Revenue | 769.60 | 100.00% |
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The company operates 3 primary manufacturing units: Unit I at Panchkula (Haryana), Unit II at Baddi (Himachal Pradesh), and European operations through Venus Pharma GmbH (Germany) and Venus Pharma Kft (Hungary). R&D operations are concentrated at the DSIR-accredited Venus Medicine Research Centre (VMRC) in Baddi.
📊 The Financial Health: The Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
| Financial Metric (₹ Cr) | FY 2025-26 | FY 2024-25 | FY 2023-24 | Latest YoY (%) |
|---|---|---|---|---|
| Revenue from Operations | 769.60 | 652.89 | 586.52 | +17.88% |
| EBITDA (Operating Profit) | 159.86 | 84.49 | 70.52 | +89.21% |
| Profit After Tax (PAT) | 102.79 | 45.31 | 33.90 | +126.86% |
| Total Equity (Net Worth) | 663.75 | 560.95 | 487.55 | +18.33% |
| Net Operating Cash Flow | 155.77 | 86.44 | 28.49 | +80.21% |
Earnings, Expenses, & Take-Take Profits (Consolidated Profit & Loss)
| Consolidated P&L Line Item (₹ Crores) | FY 2025-26 | FY 2024-25 | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 769.60 | 652.89 | +17.88% |
| Other Income | 12.58 | 15.95 | -21.13% |
| Total Income | 782.18 | 668.84 | +16.95% |
| Cost of Materials Consumed | 387.98 | 348.77 | +11.24% |
| Purchase of Stock-in-Trade | 10.76 | 25.04 | -57.03% |
| Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress | (11.47) | 4.81 | N/M |
| Employee Benefit Expenses | 88.68 | 80.49 | +10.18% |
| Finance Costs | 0.04 | 0.07 | -42.86% |
| Depreciation and Amortization Expenses | 25.67 | 22.51 | +14.04% |
| Selling, Manufacturing & Administration Expenses | 128.20 | 107.16 | +19.63% |
| Research & Development Expenses | 18.17 | 18.08 | +0.50% |
| Total Expenses | 648.03 | 606.93 | +6.77% |
| Profit Before Tax & Exceptional Items | 134.15 | 61.91 | +116.69% |
| Exceptional Items | 0.00 | 9.91 | -100.00% |
| Profit Before Tax (PBT) | 134.15 | 71.83 | +86.76% |
| Tax Expenses (Current & Deferred) | 31.36 | 26.51 | +18.29% |
| Profit After Tax (PAT) | 102.79 | 45.31 | +126.86% |
| Other Comprehensive Income (OCI) | 0.01 | (0.68) | N/M |
| Total Comprehensive Income | 102.80 | 44.63 | +130.34% |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
| Consolidated Balance Sheet Line Item (₹ Crores) | As at March 31, 2026 | As at March 31, 2025 | Latest YoY (%) |
|---|---|---|---|
| ASSETS | |||
| Property, Plant & Equipment | 125.43 | 124.70 | +0.59% |
| Capital Work-in-Progress (CWIP) | 51.36 | 26.39 | +94.62% |
| Intangible Assets & Right-of-Use Assets | 106.17 | 104.72 | +1.38% |
| Non-Current Investments & Financial Assets | 171.56 | 60.52 | +183.48% |
| Other Non-Current Assets | 3.98 | 2.47 | +61.13% |
| Total Non-Current Assets | 458.50 | 318.81 | +43.82% |
| Inventories | 129.37 | 100.49 | +28.74% |
| Current Investments | 73.80 | 29.28 | +152.05% |
| Trade Receivables | 103.28 | 112.22 | -7.97% |
| Cash and Cash Equivalents | 25.12 | 57.52 | -56.33% |
| Other Bank Balances & Financial Assets | 5.02 | 23.44 | -78.58% |
| Current Tax Assets & Other Current Assets | 58.63 | 73.96 | -20.73% |
| Total Current Assets | 395.20 | 396.92 | -0.43% |
| Total Assets | 853.70 | 715.72 | +19.28% |
| EQUITY AND LIABILITIES | |||
| Equity Share Capital | 13.37 | 13.37 | 0.00% |
| Other Equity | 650.38 | 547.58 | +18.77% |
| Total Equity (Net Worth) | 663.75 | 560.95 | +18.33% |
| Provisions & Deferred Tax Liabilities (Non-Current) | 17.15 | 18.48 | -7.20% |
| Non-Current Lease Liabilities | 11.05 | 0.00 | N/M |
| Non-Current Borrowings | 0.00 | 0.00 | N/M |
| Total Non-Current Liabilities | 28.20 | 18.48 | +52.60% |
| Current Borrowings | 0.00 | 1.69 | -100.00% |
| Trade Payables (MSME & Others) | 113.49 | 91.86 | +23.55% |
| Current Lease Liabilities & Other Financial Liabilities | 41.87 | 31.38 | +33.43% |
| Other Current Liabilities & Provisions | 6.40 | 11.35 | -43.61% |
| Total Current Liabilities | 161.76 | 136.29 | +18.69% |
| Total Liabilities | 189.95 | 154.77 | +22.73% |
Cash Flow: Tracking the Money Movement
| Consolidated Cash Flow Statement (₹ Crores) | FY 2025-26 | FY 2024-25 | Latest YoY (%) |
|---|---|---|---|
| Net Cash Generated from Operating Activities | 155.77 | 86.44 | +80.21% |
| Purchase of Property, Plant & Equipment (CapEx) | 37.66 | 9.63 | +291.07% |
| Net Cash Flow from Investing Activities | (181.57) | (76.25) | +138.12% |
| Net Cash Flow from Financing Activities | (3.12) | (1.02) | +205.88% |
| Net Increase / (Decrease) in Cash & Cash Equivalents | (28.91) | 9.18 | N/M |
| Closing Cash & Cash Equivalents | 25.12 | 57.52 | -56.33% |
Funding the Future: CapEx, CWIP, R&D & Foreign Exchange
Capital investments during the year included ₹37.66 Crores in property, plant, and equipment, while Capital Work-in-Progress (CWIP) stood at ₹51.36 Crores, reflecting ongoing capacity expansion in lyophilisation and sterile lines. Research and development expenditure amounted to ₹18.17 Crores on a standalone/consolidated operational basis (representing ~2.4% of turnover). Foreign exchange earnings stood at ₹416.86 Crores (USD 404.10M, EUR 141.58M, GBP 17.41M equivalent), while foreign exchange outgo was ₹44.52 Crores.
👥 Power & Control: Corporate Governance, Leadership & Ownership
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Pawan Chaudhary | Chairman & Managing Director & CFO | 00435503 | Promoter, Executive |
| Dr. (Mrs.) Manu Chaudhary | Joint Managing Director & Director – Technical | 00435834 | Promoter, Executive |
| Peeyush Jain | Deputy Managing Director | 00440361 | Executive Director |
| Ashutosh Jain | Executive Director (Administration & Law) | 01336895 | Executive Director |
| Akshansh Chaudhary | Executive Director & Chief Technology Officer | 08786627 | Executive Director |
| Saransh Chaudhary | Executive Director & CEO – VMRC | 08752105 | Executive Director |
| Navdeep Sud | Independent Director | 08764371 | Non-Executive, Independent |
| Dr. (Mrs.) Savita Gupta | Independent Director | 08068504 | Non-Executive, Independent |
| NPS Monga | Independent Director | 09339768 | Non-Executive, Independent |
| Jagdish Chander Sharma | Independent Director | 00195489 | Non-Executive, Independent |
| Dr. Anil Kumar | Independent Director | 10718262 | Non-Executive, Independent |
| Dr. Gurminder Singh Bedi | Independent Director | 11713102 | Non-Executive, Independent |
| Neha Kodan | Company Secretary & Compliance Officer | – | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
| Category of Shareholder | Number of Holders | Total Shares Held | % of Total Shares |
|---|---|---|---|
| Promoter Individuals (Pawan Chaudhary, Manu Chaudhary) | 2 | 3,281,946 | 24.55% |
| Promoter Body Corporate (Sunev Pharma Solutions Pvt. Ltd.) | 1 | 2,300,000 | 17.21% |
| Promoter Group Individuals | 2 | 51 | 0.00% |
| Foreign Portfolio Investors (FPIs) | 31 | 373,740 | 2.80% |
| Alternate Investment Funds (AIFs) | 6 | 160,978 | 1.20% |
| Resident Individuals (Public) | 17,312 | 5,934,236 | 44.39% |
| Bodies Corporate & LLPs | 144 | 620,035 | 4.64% |
| Non-Resident Indians (NRIs) | 393 | 217,941 | 1.63% |
| Clearing Members & HUF | 510 | 340,811 | 2.55% |
| Investor Education and Protection Fund (IEPF) | 1 | 134,041 | 1.00% |
| Escrow Account | 1 | 3,200 | 0.02% |
| Total Shareholding | 18,403 | 13,366,988 | 100.00% |
🗺️ The Corporate Family Tree: Group Structure & Strategic Investments
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
| Entity Name | Relationship | Country | % Shareholding | Turnover (₹ Crores) | Profit / (Loss) After Tax (₹ Crores) |
|---|---|---|---|---|---|
| Venus Pharma GmbH | Wholly Owned Subsidiary | Germany | 100.00% | 26.84 | 3.84 |
| Venus Pharma Kft | Step-Down Subsidiary (via GmbH) | Hungary | 100.00% | 0.00 | (0.00) |
Strategic Investments, Credit Facilities & Contingent Liabilities
The group holds mutual funds, debt-oriented instruments, and equity investments totaling ₹87.62 Crores under current and non-current financial assets. Outstanding working capital credit facilities stood at nil as the company operates debt-free. Contingent liabilities include pending tax demands of ₹0.60 Crores, disputed GST demands of ₹19.26 Crores, and capital commitments of ₹26.76 Crores.
🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans
Competitive Advantages & Economic Moats
Venus Remedies possesses strong economic moats built on three decades of specialized sterile injectable manufacturing, extensive regulatory approvals (1,100+ global MAs across 100+ countries), and proprietary R&D platforms developed at VMRC. Holding two USFDA QIDP designations for critical anti-infective candidates (VRP-034 and VRP-048) places the company in an elite global tier for antimicrobial resistance research. Furthermore, its zero-debt balance sheet and proprietary digital automation tools (Project Hyperlink, ICD Online) provide operational agility and cost competitiveness.
What Could Go Wrong? Key Challenges & Business Risks
Key business risks include exposure to international regulatory scrutiny, potential price controls in domestic and export markets, volatility in active pharmaceutical ingredient (API) procurement costs, and foreign exchange fluctuations. Compliance failures in sterile manufacturing or delays in clinical pipeline progression could also impact long-term growth.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
The company’s Mission 2030 strategy outlines ten institutional milestones centered on advancing anti-infective pipelines toward commercialization (including Phase 1 clinical trials for VRP-034), expanding manufacturing capacity via the greenfield Venus Industrial Park (VIP), deepening digital transformation through AI-first workflows, and scaling high-value specialty portfolios across regulated markets.
The Verdict: Strategic Outlook & Conclusion
FY 2026 marks a structural inflection point for Venus Remedies, characterized by zero debt, consolidated net profits crossing ₹100 Crores, robust operating cash generation, and the resumption of dividend payouts after a decade. With a reinforced balance sheet, proprietary R&D assets, and a scalable manufacturing footprint, the company is well-positioned for sustainable long-term value creation.
Frequently Asked Questions (FAQs) About Venus Remedies
Q1: What is the core business and product portfolio of Venus Remedies?
Venus Remedies is a research-driven pharmaceutical company specializing in complex injectable formulations, anti-infectives, oncology, and critical care therapeutics, supported by over 195+ commercial products and 1,100+ global marketing authorisations.
Q2: What were the key financial results of Venus Remedies for FY 2025-26?
For FY 2025-26, the company reported consolidated revenue from operations of ₹769.60 Crores, EBITDA of ₹159.86 Crores, and a Profit After Tax (PAT) of ₹102.79 Crores.
Q3: Who are the promoters and key managerial personnel leading the company?
The company is promoted by Pawan Chaudhary (Chairman, Managing Director & CFO) and Dr. (Mrs.) Manu Chaudhary (Joint Managing Director), alongside executive leaders Peeyush Jain, Ashutosh Jain, Akshansh Chaudhary, and Saransh Chaudhary.
Q4: Where are Venus Remedies’ manufacturing facilities and markets located?
The company operates manufacturing plants in Panchkula (Haryana) and Baddi (Himachal Pradesh), alongside European operations in Germany and Hungary, serving commercial markets across more than 100 countries worldwide.
Q5: What is the debt profile and financial strength of the company?
Venus Remedies maintains a landmark zero-debt balance sheet with robust liquidity, net operating cash flows of ₹155.77 Crores, and a total net worth (equity) of ₹663.75 Crores.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.venusremedies.com